The trough levels of bevacizumab significantly affect the outcome of the treatment in patients with metastatic colorectal cancer: A Turkish Oncology Group study.

Akbulut, HakanOcal, MugeSonugur, Fatma GizemAbgarmi, Samira AbdiBabahan, CansuAkay, BusraArslan, Ulku Yalcintas2024-02-232024-02-2320180732-183X1527-7755https://doi.org/10.1200/JCO.2018.36.15_suppl.e15553https://hdl.handle.net/20.500.12452/15084[Abstract Not Availabe]eninfo:eu-repo/semantics/closedAccess[Keyword Not Available]The trough levels of bevacizumab significantly affect the outcome of the treatment in patients with metastatic colorectal cancer: A Turkish Oncology Group study.Conference Object3615Q1WOS:000442916005036Q110.1200/JCO.2018.36.15_suppl.e15553